{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-215574","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.170111+00:00","generated_at":"2026-06-24T02:00:55.058038+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galera reports Q2 net loss $14.6M ($0.54/sh); NDA for avasopasem on track by end of 2022","bullets":["Net loss $14.6M ($0.54 per share) in Q2 2022, compared to $22.4M ($0.88/sh) in Q2 2021.","R&D expenses $6.7M (down from $16.0M YoY); cash and investments $52.0M as of June 30, 2022.","Phase 3 ROMAN data: avasopasem reduced SOM incidence and days; NDA submission on track for end of 2022.","Phase 1 GRECO-1: rucosopasem+SBRT showed 6/7 patients with partial response or stable disease; Phase 2 enrollment completion expected 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-215574","json":"https://secwatch.observer/filing/0001193125-22-215574.json","markdown":"https://secwatch.observer/filing/0001193125-22-215574.md","text":"https://secwatch.observer/filing/0001193125-22-215574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522215574/0001193125-22-215574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312522215574/d375942d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:00:55.058038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}